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Molecular basis of osteogenesis imperfecta 
and future medical treatment
Ljubica Boban1, Eduard Rod2, Mihovil Plečko3, Ana Marija Slišković4, 
Juraj Korbler5, Dragan Primorac2,6,7,8,9,10,11
Osteogenesis imperfecta (OI) or brittle bone disease is a metabolic bone disease characterized by bone fragility, low bone mass, and 
increased rate of bone fractures and deformities. Clinical presentation in OI patients shows wide variability ranging from mild to se-
vere and lethal OI types. Advances in molecular biology and studies on animal OI models found at least 16 new genes involved in OI 
pathogenesis. The majority of mutations are autosomal dominant aff ecting COL1A1 and COL1A2 genes responsible for collagen 
synthesis. The remaining 10%-15% of mutations in OI are autosomal recessive and aff ect genes involved in various metabolic bone 
processes. Progress in understanding bone metabolism and genetic engineering off ers new potential therapeutic opportunities that 
are under diff erent stages of investigation.
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INTRODUCTION
Bone tissue is a type of dense connective tissue consisting 
of living cells embedded in a mineralized organic matrix (1). 
It has mechanisms to grow and change its shape and size to 
suit varying stressors including the ability to resist mechani-
cal forces. Bone cells include osteoblasts, osteocytes and 
osteoclasts. Osteoblasts synthesize bone matrix and partici-
pate in its mineralization (2). Osteocytes are thought to be 
sensory cells that are involved in signaling processes inside 
the bone. They are connected to other osteocytes through 
their projections, which extend through the canaliculi. Os-
teoclasts are large multinucleated cells responsible for bone 
resorption. The mineralized matrix of bone tissue has an 
 organic and an inorganic component. Organic component 
of bone includes collagen, proteoglycans, matrix proteins, 
cytokine and growth factors (2). The vast majority of the 
 organic matrix is type I collagen that provides tensile 
strength (3). Inorganic (mineral) composition of bone is 
 primarily formed from salts of calcium and phosphate. The 
majority of salts are hydroxyapatite and osteocalcium 
 phosphate, which provide compressive strength. Thus, the 
collagen and mineral together are a composite material 
with an excellent tensile and compressive strength, which 
can bend under strain and recover its shape without dam-
age (4).
Bone metabolism (bone turnover) relies on complex signal-
ing pathways and control mechanisms to achieve proper 
rates of growth and diff erentiation. These controls include 
the action of several hormones, including parathyroid hor-
mone (PTH), vitamin D, growth hormone, steroids, and cal-
citonin, as well as several bone marrow-derived membrane 
and soluble cytokines and growth factors (4).
A number of bone turnover markers (BTMs) can now be de-
termined using commercial tests. Bone turnover markers 
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are generally subdivided into two categories: biomarkers of 
bone formation, and biomarkers of bone resorption and os-
teoclastogenesis. Bone formation markers derive from the 
osteoblastic activity and include bone alkaline phosphatase 
(BSAP), osteocalcin (OC), N-terminal propeptide (PINP), and 
C terminal propeptide of type I procollagen (PICP) (5). The 
markers of bone resorption and osteoclastogenesis result 
from degradation of type I collagen such as intermolecular 
crosslinks pyridinoline (PYD) and deoxypyridinoline (DPD), 
C-terminal telopeptide (CTX), N-terminal telopeptide (NTX) 
and matrix-metalloproteinase (MMP)-generated (CTXMMP 
or ICTP) type I collagen fragments, the enzymes secreted by 
osteoclasts, i.e. tartrate-resistant acid phosphatase 5b iso-
form (TRAP-5b), and receptor activator of nuclear factor NF-
κB ligand (RANKL). Several prospective cohort and case-
control studies suggest that increased BTM levels predict 
fractures independently of age, BMD, and prior fracture.
Collagens are ubiquitous molecules in all multicellular ani-
mals (4). As an important ingredient of the extracellular ma-
trix, bones, cartilages and other structures in the body, 
many cells have an ability to produce collagen molecules. 
Collagens are divided into several types: fi brillar collagens 
(types 1, 2, 3 and 5), fi bril-associated collagens (types 6 and 
9), sheet forming and anchoring collagens (types 4, 7 and 
15), transmembrane collagens (types 13 and 17), and host 
defense collagens (collectins, class A scavenger receptors 
on macrophages). Fibrillar collagens are most abundant in 
the extracellular matrix of connective tissues such as ten-
dons and cartilage, making the majority of its volume (4).
Two genes are involved in the synthesis of type I collagen 
molecule: COL1A1 located on chromosome 17 and COL1A2 
on the long arm of chromosome 7. Two pro-alpha 1 chains 
are transcribed from COL1A1, and one pro-alpha 2 chain 
from COL1A2, which in the end form a triple helix when the 
synthesis and post translation modifi cations are done (6).
The gene transcript initiates the formation of collagen on 
the ribosomes of the rough endoplasmic reticulum. After 
translation, three individual pre-pro-collagen chains are 
formed: two alpha 1 chains and one alpha 2 chain, which 
are transported into the reticulum where additional pro-
cessing is done and the collagen fi brils are fold into a triple 
helix (4).
Within the endoplasmic reticulum, lysine and proline resi-
dues of the propetide are hydroxylated by enzymes to pro-
mote the stability and glycosylation of the triple helix. Ad-
ditionally, three alpha chains are packed together in such a 
way to make repeating glycine-x-y patterns, which give 
signifi cant stability to the triple helix. Glycine is the smallest 
amino acid that can fi t in the tightly packed axes without 
causing chain distortion.
After the collagen molecule leaves the endoplasmic reticu-
lum, it is then called procollagen and is transported to the 
Golgi apparatus, where it is further modifi ed and prepared 
for exocytosis. During transport out of the cell, certain pro-
collagen processing and fi bril assembly has already started 
in compartments between the Golgi apparatus and the cell 
membrane. Recent studies suggest that the procollagen 
molecule is transported in two ways, slow and fast. In the 
reticulum, procollagen is recognized by a receptor gate-
keeper and goes through a pore that transverses both the 
endoplasmic reticulum and plasma membranes. This allows 
fast exit from the cell that requires little energy and is driven 
by diff usion gradient. The slow transport goes through the 
Golgi apparatus via vesicle (6).
Once in the extracellular matrix, additional propeptides are 
cleaved on both ends of the molecule, and such process 
results in the formation of type I collagen that crosses links 
with the other type I collagen molecules to form fi brils and 
fi nally collagen fi bers.
Collagen is one of the main protein components of the ex-
tracellular matrix, along with proteoglycans, hyaluronic 
acid, laminins and fi bronectin. Together they form a highly 
organized support medium that is important in regulating 
cell and tissue development and function. Diff erent combi-
nations of the main proteins allow the extracellular matrix 
to act with specifi city in diff erent tissues of the body. Helix 
form of the collagen molecule has excellent force dispersal 
properties (6).
Type I collagen molecules have an excellent resistance to 
tension and make a primary substance in the bone. Fibers 
of type I collagen are also the most common protein in the 
extracellular matrix, tendons and ligaments, as well as cap-
sules of many organs and dentine cementum.
Mutations of the collagen genes cause several other dis-
eases; Caff ey disease, Ehler-Danlos syndrome, osteogenesis 
imperfecta and dermatofi brosarcoma protuberans are 
caused by mutations in the COL1A1 gene, whereas COL1A2 
gene is linked to the Ehler-Danlos syndrome and osteogen-
esis imperfecta (7).
ETIOLOGY OF CHANGES IN OSTEOGENESIS 
IMPERFECTA
Osteogenesis imperfecta (OI) is an inherited connective tis-
sue disease characterized by variability of clinical presenta-
tion (7, 8). Presumably, large variability in clinical presenta-
tion is a consequence of the high number of genes involved 
in the disease pathogenesis and diversity of genetic muta-
tions. Most frequently, mutations occur in the genes respon-
sible for encoding alpha-1 and alpha-2 chains of type I col-
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lagen, or in the genes responsible for posttranslational mod-
ifi cation of type I collagen. In most cases (85%-90%), OI is 
caused by an autosomal dominant genetic defect, in which 
only one gene copy contains pathogenic variant (9-11). 
Around 10%-15% of OI cases are caused by recessive genetic 
mutations inherited from both healthy parents that do not 
have OI, however, they both carry mutation in their DNA 
(12). Recent molecular and clinical investigations found 
more than 16 genetic and molecular phenotypes of OI.
The most common mutations that cause OI are autosomal 
dominant mutations in COL1A1 (17q21.31-q22) or COL1A2 
(7q22.1) genes responsible for the synthesis of alpha-1 and 
alpha-2 chains of type I collagen (10, 11). Mutations in CO-
L1A1 and COL1A2 cause OI type I-IV. In general, OI-causing 
mutations can be divided into quantitative and structural 
defects. Mutations that cause quantitative defects can re-
sult in a microsense frame shift or premature stop codon, 
which leads to the production of mutant mRNA. However, 
there are mRNA products from the other gene copy that 
was not aff ected by the mutation. The end result of protein 
synthesis from this mRNAs is a mixture of normal and ab-
normal collagen chains, forming half of the normal amount 
of healthy collagen type I. Clinical presentation of quantita-
tive defect variant is usually a mild OI phenotype I. Struc-
tural defects result in the synthesis and secretion of abnor-
mal collagen molecules. Mutations alter chain sequence in 
the triple helical domain and result in a wide phenotypic 
range from lethal type (OI type II), severe (type III) to moder-
ate type IV. Most frequently, these mutations cause substi-
tution of one of the glycine residues in alpha chains, which 
have a crucial role in helix formation.
Osteogenesis imperfecta type V is caused by an autosomal 
dominant mutation of IFITM5 gene. It is the only dominant-
ly inherited type of OI that is not due to collagen structural 
abnormalities. Mutation generates the alternative in-frame 
start codon and adds 5 residues to the N-terminus of bone 
restricted IFITM-like protein (BRIL). BRIL is highly expressed 
in osteoblasts and developing bone. Alterations in BRIL 
function lead to insuffi  cient bone mineralization (13).
Osteogenesis imperfecta type VI is caused by a mutation of 
SERPINF1 gene, which encodes pigment epithelium-de-
rived factor (PEDF), a glycoprotein involved in various pro-
cesses including neurotrophic and antiangiogenic process-
es and bone mineralization (14).
Mutations of the genes encoding cartilage-associated pro-
tein (CRTAP) and prolyl 3-hydroxylase 1 (P3H1 encoded by 
LEPRE1) were the fi rst identifi ed causes of recessive OI, now 
known as OI type VII (CRTAP) and VIII (LEPRE1). The lack of 
P3H1 or CRTAP causes severe to lethal bone dysplasia. Also, 
mutation of PPIB, discovered later, causes lack of cyclophilin 
B (CyPB), resulting in severe to lethal bone dysplasia named 
OI type IX. CRTAP, P3H1 and CyPB form a complex within the 
ER that post-translationally modifi es specifi c proline resi-
dues (14). Also, the complex has a function as a peptidyl-
prolylcis-trans isomerase (PPIase) and as a chaperone, pre-
venting type I collagen chains from forming premature ag-
gregates in the ER15.
Osteogenesis imperfecta type X is caused by a mutation in 
the SERPINH1 gene, which encodes heat-shock protein 47 
(HSP47). The function of HSP47 is to recognize the folded 
state of type I procollagen trimer in the ER and help main-
tain it. The FKBP10 gene encodes for FK506-binding protein 
10 (FKBP10 or FKBP65), an ER-localized PPIase and a chaper-
one molecule. FKBP65 has multiple ligands, including type I 
collagen and elastin. It is involved in the folding of collagen 
type I. Mutations of this gene cause OI type XI and can also 
cause Bruck syndrome type I (12, 14).
In addition, changes in several other genes involved in os-
teoblast diff erentiation can cause OI, e.g., SP7 (OI type XII), 
BMP1 (OI type XIII), TMEM38B (OI type XIV), WNT1 (OI type 
XV), CREB3L1 (OI type XVI), SPARC (OI type XVII) and MBTPS2 
(OI type XVIII) (12, 14).
EPIDEMIOLOGY, PATHOLOGY AND PATHOGENESIS 
OF OSTEOGENESIS IMPERFECTA
The prevalence of OI is one case per 20 000 births (15). The 
actual prevalence could be even higher because milder 
variants often remain unrecognized. According to popula-
tion based data, OI is described worldwide and its preva-
lence is relatively equal and stable.
The pathogenesis of bone disease in OI can not only be ex-
plained by quantitative or qualitative type I collagen abnor-
malities and diff erent animal models were created in order 
to elucidate bone metabolism at the molecular and cellular 
level. Genetic heterogeneity including the large number of 
genes involved in OI pathogenesis and their pathogenic 
variants, as well as additional unknown modifying mecha-
nisms have made OI pathophysiology still incomprehensi-
ble (8, 15).
Bone is a dynamic tissue in which the process of bone for-
mation and resorption is constantly being carried out, 
whereby in physiologic conditions these two processes are 
in equilibrium. In OI patients, bone resorption is more inten-
sive than formation, which ultimately leads to reduction in 
total bone mass. Animal model studies have shown insuffi  -
cient osteoblast productivity, although their m-RNA-mea-
sured collagen synthesis is constantly present (8). In vivo 
and in vitro studies have revealed altered osteoblast diff er-
entiation in OI bone, leading to an increase in immature os-
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teoblast synthesis. Premature osteoblast/osteocyte precur-
sor cells cause osteoclastogenic induction and an increase 
in osteoclast number (16).
Osteoblasts have a capability to diff erentiate into osteo-
cytes, the cells involved in the control of various bone 
growth stimuli from the outside. Osteocytes produce bone 
control molecules that can modulate osteoclast activity. 
RANKL is a supporting molecule in osteoclast precursor dif-
ferentiation, while sclerostin molecule acts as a negative 
regulator of bone mass in osteoblasts. Ultrastructural ex-
amination of OI bone tissue also showed an increase in the 
number of osteocytes, with some lacunae containing mul-
tiple osteocytes.
Bone mineralization in OI is increased, with small but plenti-
ful mineral crystals associated with low mechanical strength 
(17). Completely disorganized cytoskeleton was found in 
patients with lethal or severe outcomes. It is not clear 
whether cytoskeletal organization is a primary or secondary 
modulator in OI (18). Taken all together, the outcome of all 
previously described interactions is the formation of fragile 
bone susceptible to fractures. 
CLINICAL PRESENTATION
Osteogenesis imperfecta is a multisystem disorder that 
mostly aff ects tissues composed of type I collagen, i.e. 
bones, teeth, and ligaments (15, 19). The major features in 
OI patients are listed below:
Bone fragility and increased fracture rate depending on dis-
ease type. As a consequence of fractures and inappropriate 
bone healing, scoliosis, barrel chest and long bone deformi-
ties are frequently seen.
Craniocervical junction anomalies are found in 30% of all OI 
patients and include basilar invagination, basilar impression 
and platybasia as most frequent in OI.
Growth retardation and short stature are more pronounced 
in recessive than in dominant forms of the disease.
TABLE 1. Genetic basis, pathogenesis and clinical features of OI (19)
OI type Gene Pathogenesis Clinical features Disease severity
I COL1A1 COL1A2 Defects in collagen synthesis, 
structure, or processing
Increased fracture rate, blue sclerae, conductive hearing loss  Mild
II COL1A1 COL1A2 Defects in collagen synthesis, 
structure, or processing
Intrauterine fractures, minimal calvarial mineralization, 
rib and long bone fractures and deformities 
Lethal
III COL1A1 COL1A2 Defects in collagen synthesis, 
structure, or processing
Frequent fractures, bone deformities, short stature, 
kyphoscoliosis, immobility
Moderate to severe
IV COL1A1 COL1A2 Defects in collagen synthesis, 
structure, or processing
Recurrent fractures, osteoporosis, long bone deformities Mild to moderate
V IFITM5 Defect in bone mineralization Calcifi cation of interosseous membrane of the forearm and 
hyperplastic callus formation
Variable
VI SERPINF1 Defect in bone mineralization Recurrent fractures, high levels of alkaline phosphatase Moderate to severe
VII CRTAP Defects in collagen 
modifi cation
Chondrodysplasia, rhizomelia, patient usually born 




Defects in collagen 
modifi cation
Rhizomelia, coxa vara and popcorn metaphysis seen on x-ray Severe to lethal
IX PPIB Defects in collagen 
modifi cation
Bowed femurs with anterior bowing of the tibiae Severe
X SERPINH1 Defects in collagen folding 
and cross-linking
Macrocephaly, an open anterior fontanel, high and prominent 
forehead, hypoplasia of the midface with shallow orbits, blue 
sclerae, dentinogenesis imperfecta, scoliosis, joint laxity, 
nephrocalcinosis and chronic lung disease
Severe
XI FKBP10 Abnormal cross-linking of 
collagen molecule
Joint contractures Moderate to severe
XII SP7 Defects in osteoblast 
development with collagen 
insuffi  ciency
Fractures in lower extremities, delayed dental eruption, 
midface hypoplasia
Mild






cleavage defect, calcium 
channel defect, defects in 
ER-stress transducer regulator 
molecule
Sporadic reports, increased fracture rate, osteoporosis Moderate to severe
OI, osteogenesis imperfecta
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Dentinogenesis imperfecta: abnormalities in teeth color 
and quality.
Hearing loss related to combined conductive and sensori-
neural defi cits.
Cardiopulmonary complications are a major cause of death 
in OI patients. During childhood, there are rib fractures lead-
ing to respiratory insuffi  ciency, whereas in adulthood dilata-
tion of aortic root and hypertension are frequently reported.
Blue sclera is used as a feature that diff erentiates type I from 
type IV.
Additional features: triangular face and macrocephaly.
Based on clinical and radiological fi ndings, OI is originally 
classifi ed into four types, I-IV (Sylence 1979) (20). Advantag-
es in molecular genetics have delineated 18 molecularly 
defi ned OI types (I-XVIII). Their molecular and clinical fea-
tures are presented in Table 1 (19).
GENETIC COUNSELING
In order to get complete care in OI patient, molecular diag-
nosis and pathogenic variant detection should be routine 
procedures in clinical practice. Genetic testing and counsel-
ing should be provided to all OI aff ected individuals, their 
parents and off spring, as well as individuals at risk (15, 19).
Detailed family history and clinical evaluation of parents 
and proband is a key prerequisite for appropriate genetic 
testing and evaluation (21, 22). Even subtle clinical features 
in parents such as discrete limb length abnormalities can be 
refl ection of parental mosaicism. After clinical OI diagnosis, 
the next step in patient evaluation is molecular diagnosis 
obtained by the next generation sequencing techniques 
(NGS). At present, there are various approaches using diff er-
ent gene panels involved in OI pathogenesis. For economic 
reasons, in families with a single proband it is rationale to 
make fi rst screen for COL1 genes, followed by complete se-
quence analysis of other OI genes in case of negative re-
sults. If the results of sequence analysis are negative, addi-
tional testing using array or MLPA that identifi es exon or 
whole-gene deletions/duplications is required (19).
In cases where more than one family member is aff ected, it 
is recommended to investigate the whole OI gene panel in 
the proband using NGS methods as the fi rst step (19).
Genetic testing in parents is made after positive results in 
the proband in order to determine carrier status and inher-
ited risks in future pregnancies. In most cases, pathogenic 
variants are absent in parents suggesting de novo genetic 
changes that occurred before conception in either one spe-
cifi c sperm or egg that contributed to the pregnancy. Also, 
pathogenic variants can originate from parental mosaicism 
that makes the recurrence risks in future pregnancies higher 
than it would be expected. The presence of mosaic carrier 
status in the parent can reach recurrence risks equivalent to 
the fully heterozygous status (23). Parental mosaicism 
should be considered in families with recurrent OI and neg-
ative results of NGS panel testing. Although NGS techniques 
are a valuable method for parental mosaicism detection, in 
some cases it can be missed due to the low grade of mosa-
icism and technical diffi  culties (23). In these cases, it is rec-
ommended to perform additional NGS analysis using more 
than one tissue (blood, buccal, saliva, sperm).
Although molecular genetic testing methods can off er pre-
cise and quick detection of pathogenic variant, genetic 
counseling and providing information on disease type and 
prognosis is complicated in routine clinical practice. Defi ni-
tive genotype-phenotype correlation that could explain 
and predict all clinical features in OI patients does not exist 
(24). Autosomal dominant mode of inheritance carries a 
50% risk of genetic transmission in future pregnancies, but 
in practice it is not always easy to predict phenotype in the 
off spring. Autosomal dominant mode of inheritance and its 
variability in clinical expression, presence of additional 
modifi er genes, and interfamilial variability even among 
family members with the same mutation complicate ge-
netic counseling in OI patients. Disease phenotype in OI 
patients is mostly determined by classes of mutation, e.g., 
mild OI type caused by fi rst class of mutation (quantitative 
collagen defects) and severe OI type caused by second type 
(structural collagen defects). Besides the above-mentioned 
classes of mutations, phenotype features depend on the af-
fected alpha type I collagen chain, position of the mutation, 
substituting amino acid, and/or combination of these vari-
ables (24).
Although rare, autosomal recessive forms of OI should be 
considered when unaff ected parents have more than one 
child aff ected, in cases of parental consanguinity, and in 
cases with negative results of standard NGS panel covering 
COL1A1 gene. In these cases, it is recommended to perform 
analysis in the proband using whole OI gene panel (19). Au-
tosomal recessive forms of OI are associated with 25% re-
currence risk in parents of aff ected proband. Even in family 
members that share the same mutation, wide phenotypic 
variability has been demonstrated. Consequently, precise 
molecular and clinical diagnoses are a prerequisite for coun-
seling in these patients.
Prenatal and preimplantation genetic diagnosis can be ap-
plied in pregnancies/fetuses at risk. Prenatal diagnosis 
should be off ered in all pregnancies with positive family his-
tory, i.e. OI in parent and sibling (19). Molecular genetic test-
ing is available for all OI types if the mutation is known in 
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the family. The source of DNA for prenatal analysis are CVS at 
10 weeks or amniocytes at 10-15 gestational weeks (19).
Prenatal ultrasound diagnosis in low risk pregnancies may 
identify fetus with fi ndings suggestive of OI. Molecular ge-
netic testing can be off ered but inability to identify muta-
tion does not exclude OI diagnosis in the patient. 
FUTURE TREATMENT OF OSTEOGENESIS IMPERFECTA 
Advances in molecular medicine, genetic engineering and 
transplantation have led to new potential therapies based on 
stem cell transplantation and genetic engineering (25, 26).
Cell based therapy using stem cells 
Major characteristics of stem cells are capability of diff eren-
tiation into multi-lineage cells and self-renewal capacity. 
Based on their origin, stem cells are divided into diff erent 
categories: embryonic stem cells, induced pluripotent stem 
cells, and adult stem cells. Mesenchymal stem cells are adult 
stem cells located in various animal and human tissues. 
Their easy accessibility and ability of multi-lineage diff eren-
tiation in mesodermal tissues such as osteoblasts, osteo-
cytes and chondrocytes makes them attractive for bone 
disease treatment (26). Preclinical trials of bone marrow/
mesenchymal stem cell transplantation in various OI trans-
genic murine OI models (OI type III, IV) using diff erent cell 
delivery systems (intraosseous, intravenous, liver injection) 
were performed (26). Transplantation methods in preclinical 
animal trials achieved low donor bone engraftment in af-
fected animals of 0.3%-28% but transplanted cells succeed-
ed to diff erentiate into osteoblasts (27). Results of bone en-
graftment depended on the type of transplant (whole bone 
marrow, mesenchymal stem cells, fetal blood mesenchymal 
stem cells), transplantation technique, and age of animal 
model. Despite the low bone engraftment, biomechanical 
improvements in bone matrix quality, decreased fracture 
rates and lethality in aff ected animals were achieved (28).
Favorable results in animal OI models encouraged scientists 
to apply these methods in humans. First therapeutic use of 
allogeneic bone marrow transplantation from HLA matched 
siblings in OI patients was made by Horowitz et al., who found 
an increase in growth velocity and mineral content and re-
duction in fracture rates (29). Initial positive eff ects of this 
therapy were not sustained over time and patients under-
went treatment with isolated bone marrow stem cells (BM-
MSCs) 18 months after initial transplantation. Post transplan-
tation BM-MSCs application strengthened previously achie-
ved favorable outcomes in these patients. First in utero 
transplantation was performed in a female OI fetus using HLA 
mismatched male fetal MSCs. Post transplantation monitor-
ing in this patient found three bone fractures, normal growth 
rate and normal psychomotor development in the fi rst two 
years. The latest transplantation experiences came from 
Götherström et al., who made prenatal and postnatal trans-
plantation of human fetal mesenchymal stem cells (hfMSC) in 
two OI patients with severe type. Prenatal and postnatal 
transplantation improved growth velocity in these patients, 
and no new fractures were observed over time. Both patients 
showed no alloreactivity to donor hfMSCs or possible toxic 
eff ects of transplantation procedure (30).
Despite previously mentioned favorable results using trans-
plantation methods, there is still a large number of ambi-
guities. A small number of treated patients and conse-
quently the impossibility of statistically based conclusions 
prevent the application of these methods in routine clinical 
practice.
In order to defi ne optimal therapeutic approach, additional 
basic and clinical investigations are necessary. From the cur-
rent point of view, the researcher key points are the time of 
transplantation, appropriate type and source of stem cells 
regarding their proliferation, diff erentiation and viability af-
ter transplantation. Another area of interest is bone micro-
environment after transplantation, signal pathways that 
provide osteogenic and mineralization potential, as well as 
immunogenic response of the host. 
Gene therapy
Correction of the gene defect would be the most desirable 
therapy in OI patients in the future. According to current 
literature data, several gene therapeutic strategies are ori-
ented towards mutant collagen transcripts (31).
It is well known that the pathogenic gene variants produc-
ing structurally abnormal collagen chains usually cause se-
vere phenotypes in OI patients. One of the recent gene 
therapy approaches based on mutant gene silencing in-
cludes suppression of mutant allele resulting in their haplo-
insuffi  ciency and consequently conversion of severe OI 
phenotype with structural collagen defect into less severe 
quantitative defect (31). Gene therapy strategies aiming at 
silencing mutant collagen transcripts use several method-
ological approaches, i.e. antisense oligodeoxyribonucleo-
tides (ODNs), short interfering RNA (siRNA), and hammer-
head ribozymes. Antisense ODNs are small molecules that 
can hybridize to target RNA and cause their degradation 
and also inhibit protein translation. The siRNA is able to in-
corporate in nuclease-containing multiprotein complex 
RISC (RNA-induced silencing complex) and then guided to 
target mRNA and consequently degraded. Hammerhead 
ribozymes present another type of synthetic RNA mole-
cules that could bind to mutant RNA and cause their degra-
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dation. All of these strategies were tested using in vitro or ex 
vivo model and to a lesser extent animal OI models (30, 31). 
Results of in vitro and ex vivo investigation of a siRNA tool to 
allele specifi c COL1A1 gene silencing in mouse for classic OI 
showed reduction in mutant RNA transcription to up to 
50%, while mutant protein was reduced by about 40%. Al-
lele dependent silencing of COL1A2 in single heterozygous 
individual using small interfering RNAs in OI patient de-
creased overall COL1A2 transcription by around 70%, mostly 
due to silencing of T allele (32).
Although promising, at this moment, the therapeutic ap-
proach described is still in the experimental use. The com-
plexity of its use derives from the fact that it requires spe-
cifi c design of silencing molecules (siRNA) complementary 
to target sequence/allele, creation of available carrier that 
could export it into target cells, and well defi ned technical 
details regarding application (32).
These techniques require additional investigations to deter-
mine their eff ect on other parts of the gene with similar or 
partially complementary sequences, as well as the possible 
undesirable eff ects. 
Future perspectives
Based on the previously described experimental therapies, 
a combination of gene and cell therapy could be one of the 
future treatment options.
Research in the fi eld of stem cell biology revealed induced 
pluripotent stem cells (iPSCs) to be superior to mesenchy-
mal stem cells. iPSCs can be derived directly from adult tis-
sues, off er large number of cells, and eliminate the necessity 
of adequate HLA donor. Discovery of the new agents for 
stem cell mobilization, signaling pathways in their microen-
vironment will allow higher amount of transplantable cells 
and available conditioning in treated patient.
The current level of science development off ers several 
techniques of genome editing that could be used in gene 
correction. CRISPR/Cas9-based technologies can be used in 
editing single or multiple genes in various tissues. Using 
specifi c RNA endonucleases with a synthetic guided RNA it 
is possible to recognize the site- specifi c DNA mutant loci 
and cleavage. Another potential genome editing tools in OI 
patients could be transcription activator-like eff ector nucle-
ases (TALENs) and zinc fi nger nucleases (ZFNs). These tech-
niques usually require vector (viral or plasmid). Despite rap-
id progress in the fi eld of genome editing techniques and 
awareness of their clinical signifi cance, guidelines for its use 
and safety in preclinical and clinical trials are still lacking. Al-
though these techniques off er great opportunities, their ap-
plication in clinical practice is burdened with potential risks 
of unfavorable immune response and genotoxicity (33).
Heterogeneous genetic basis in OI and raising number of 
pathogenic gene variants complicate the process of gene 
editing in these patients. Also, the variability of OI clinical 
presentation imposes doubts in an unique therapeutic ap-
proach in OI patients.
It is expected that OI treatment would be personalized over 
time and oriented to single patient and his specifi c needs 
based on genetic, biochemical and pathophysiological 
characteristics and clinical presentation, as well as safety 
concerns (34).
Currently, bisphosphonates are the most commonly used 
drugs in both pediatric and adult OI population (35). 
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S A Ž E T A K
Osteogenesis imperfecta – molekularna osnova 
i lijekovi budućnosti
Ljubica Boban, Eduard Rod, Mihovil Plečko, Ana Marija Slišković, Juraj Korbler, Dragan Primorac
Osteogenesis imperfecta (OI) ili bolest krhkih kostiju je metabolička bolest kostiju obilježena krhkim kostima, niskom koštanom 
 masom i povišenom stopom lomova i deformiteta kostiju. Klinička prezentacija bolesnika s OI veoma je raznolika, od blagog do 
teškog i smrtonosnog tipa OI. Napretkom molekularne biologije i istraživanjima na životinjskim modelima OI nađeno je najmanje 
16 novih gena uključenih u patogenezu OI. Većina mutacija su autosomno dominantne i zahvaćaju gene COL1A1 i COL1A2 koji su 
odgovorni za sintezu kolagena. Preostalih 10%-15% mutacija u OI su autosomno recesivne i zahvaćaju gene uključene u razne 
 metaboličke procese u kostima. Sve bolje razumijevanje metabolizma kostiju i genetski inženjering nude nove potencijalne terapijske 
mogućnosti koje su u različitim fazama ispitivanja.
Ključne riječi: osteogenesis imperfecta, kolagen tip I, molekularna genetika, genska terapija, matična stanica
